Profiel
Yoshihisa Sasou is currently a Director at Medicago, Inc. since 2013.
Previously, he worked as a General Manager-Corporate Communications at Mitsubishi Tanabe Pharma Corp.
Actieve functies van Yoshihisa Sasou
| Bedrijven | Functie | Begin |
|---|---|---|
Medicago, Inc.
 Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | Directeur/Bestuurslid | 18-09-2013 |
Eerdere bekende functies van Yoshihisa Sasou
| Bedrijven | Functie | Einde |
|---|---|---|
| MITSUBISHI TANABE PHARMA CORPORATION | Public Communications Contact | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 2 |
|---|---|
Mitsubishi Tanabe Pharma Corp.
 Mitsubishi Tanabe Pharma Corp. Pharmaceuticals: OtherHealth Technology Mitsubishi Tanabe Pharma Corp. engages in the research, development, manufacture, and sale of pharmaceutical products. Its products include Remicade, Ceredist, Talion, Kremezin, Maintate, Simponi, Lexapro, Tenelia, Tetrabik, and Imusera. The company was founded by Gohei Tanabeya in 1678 and is headquartered in Osaka, Japan. | Health Technology |
Medicago, Inc.
Medicago, Inc. BiotechnologyHealth Technology Medicago, Inc. is a clinical-stage biopharmaceutical company. It develops novel vaccines and therapeutic proteins to address a broad range of infectious diseases worldwide. The firm provides vaccines and therapeutic proteins based on its proprietary Virus-Like Particles and manufacturing technologies. It develops Virus-Like Particles vaccines using a transient expression system which produces recombinant vaccine antigens in plants. The company was founded by Louis-Philippe Vézina on July 17, 1997 and is headquartered in Quebec, Canada. | Health Technology |
